Research programme: glucagon-like peptide 1 mimetics - Alizyme

Drug Profile

Research programme: glucagon-like peptide 1 mimetics - Alizyme

Alternative Names: AZM 134; Research programme AZM 134 - Alizyme

Latest Information Update: 06 May 2002

Price : $50

At a glance

  • Originator Alizyme; Imperial College of Science, Technology and Medicine
  • Class Small molecules
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 May 2002 Discontinued - Preclinical for Type-2 diabetes mellitus in United Kingdom (unspecified route)
  • 01 Mar 2000 Preclinical development for Type-2 diabetes mellitus in United Kingdom (Unknown route)
  • 04 Jun 1997 Preclinical development for Type-2 diabetes mellitus in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top